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CC BY-NC-ND license (http://creativeAbstract Hepatitis C virus (HCV) is a global health burden with an estimated 170e200 million
peoples chronically infected worldwide. HCV infection remains as an independent risk factor
for chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and a major reason for liver
transplantation. Discovery of direct acting antiviral (DAA) drugs have shown promising results
with more than 90% success rate in clearing the HCV RNA in patients, although long-term con-
sequences remain to be evaluated. microRNAs (miRNAs) are important players in establish-
ment of HCV infection and target crucial host cellular factors needed for productive HCV
replication and augmented cell growth. Altered expression of miRNAs is involved in the path-
ogenesis associated with HCV infection by controlling signaling pathways such as immune
response, proliferation and apoptosis. miRNA is emerging as a means of communication be-
tween various cell types inside the liver. There is likely possibility of developing circulating
miRNAs as biomarkers of disease progression and can also serve as diagnostic tool with poten-
tial of early therapeutic intervention in HCV associated end stage liver disease. This review fo-
cuses on recent studies highlighting the contribution of miRNAs in HCV life cycle and their
coordinated regulation in HCV mediated liver disease progression.
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Hepatitis C virus (HCV) is a hepatotropic, enveloped, single
stranded and positive sense RNA virus belongs to family
flaviviridae and genus hepacivirus. The viral genome con-
tains 50 and 30 untranslated regions (UTR) that are impor-
tant for viral replication and translation. An internal
ribosome entry site (IRES) directs the synthesis of a single
precursor polyprotein of approximately 3010 amino acids,
which is cleaved by viral and cellular proteases into three
structural (core, E1 and E2) and seven non-structural (p7,
NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins. Core
protein forms the capsid, which is surrounded by a lipid
bilayer containing the glycoproteins, E1 and E2.1 These
viral proteins both singly or in coordinated manner interact
with host cellular factors and regulate various signaling
pathways to facilitate virus mediated persistent infection.2
HCV is a major cause of chronic liver disease, mostly
asymptomatic in nature. Majority of infected patients,
approximately 80%, develop persistent chronic infection
and are at high risk for liver cirrhosis and hepatocellularFigure 1 Anti-HCV drugs targeting viral life cycle. (1) HCV viral pa
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acting antivirals (DAAs) in advanced clinical development are indic
microRNA; OCLN, occludin; SR-B1, scavenger receptor class B memcarcinoma (HCC). An estimated 170e200 million peoples
worldwide are infected with hepatitis C virus3 and about
2.7e3.9 million peoples are living with HCV infection in the
United States.4 In addition, HCC and cirrhosis have been
increasing among persons infected with HCV.5,6 Advances in
anti-HCV therapy have moved into a new era with interferon
(IFN)-free regimens. Treatment options are evolving and the
once difficult to treat genotype (genotype 1) has shown sig-
nificant improvements in sustained virologic response (SVR)
rates. All-oral, IFN-free combinations of drugs are expected
to cure more than 90% of infections.7e9 Direct-acting anti-
virals (DAAs) target non-structural proteins of HCV resulting
in the termination of viral replication. Several antiviral drugs
targeting viral and host factors essential for productive HCV
infection are depicted in Fig. 1. The first NS3/4A protease
inhibitors boceprevir (Merck, Whitehouse Station, NJ) and
telaprevir (Vertex Pharmaceuticals, Cambridge, MA) have
shown improved rate of SVR in genotype 1 HCV infected pa-
tients in compared with standard pegylated interferon (PEG-
IFN) and ribavirin (RBV) therapy, but their toxicities com-
bined with PEG-IFN and RBV limited their overall efficacy.rticle interacts with several entry factors such as, SR-B1, CD81,
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miRNA in HCV infection 37Simeprevir (Janssen Pharmaceuticals, Titusville, NJ), fal-
daprevir, and asunaprevir are second-wave, first-generation
NS3/4A inhibitors that have already been or will soon be
approved. Second-generation protease inhibitors are in
clinical trials. Daclatasvir (BMS-790052, Bristol-Myers Squibb
Company) is the first approved DAA belonging to the class of
NS5A replication complex inhibitors. The potency of dacla-
tasvir is very high, and this drug is an important component of
combination regimens for all genotypes. Sofosbuvir, the first
approvedNS5B polymerase inhibitor (Gilead Sciences, Foster
City, CA) has shownhigh potency and lower drug resistance in
clinical trials. DAA drugs as anti-HCV therapeutics is highly
encouraging.7,8 However, the efficacy of these new thera-
peutic options for cirrhotic patients, the most-difficult-to-
treat population and long-term follow-up data will be
needed to confirm the excellent outcome of SVR and liver
pathogenesis. An alternative or complementary approach to
treat HCV infection is by targeting host factors that support
viral life cycle. Identifying host factors have emerged as a
promising alternative since they will have a high barrier for
viral resistance and can be broadly effective against all HCV
genotypes.10 Several host factors were identified by using
high throughput gene silencing screening approaches that
helps in HCV entry, replication, assembly and release. The
most promising host factors are miR-122, cyclophilin A (Cyp
A), scavenger receptor (SR)-BI and phosphatidylinositol-4-
kinase III a. Drugs targeting HCV entry factors, such as SR-
BI may prevent the initiation of new infection. Cyclophilins
are important host factors required for viral replication and
Cyp A has been shown to interact with NS5A.10,11 The liver
specific miR-122 binds to the 50 UTR of the HCV genome and
helps in viral replication and enhances viral protein syn-
thesis.12e15 Drugs targeting host factors, such as small
molecule inhibitor of SR-BI (ITX 5061) and cyclophilin in-
hibitors, alisporivir (Debio-025, Novartis) are in clinical tri-
als.7,10,11 Anti-HCV therapeutics targeting miR-122 showed
reduction in HCV viremia with no evidence of viral resistance
andminimal side effects in chimpanzees chronically infected
with hepatitis C.16 In addition, Miravirsen (a locked nucleic
acid-modified antisense oligonucleotide for miR-122)
showed prolonged dose-dependent reductions in HCV RNA
levels in chronic HCV genotype 1 infected patients in Phase
IIa clinical trials by Santaris Pharma (Copenhagen,
Denmark).17 These alternative approaches targeting host
factors in combination with current DAA drugs will help in
strengthening the host’s innate immunity as well as interfere
with host factors required for HCV induced pathogenesis.MicroRNA biogenesis and its regulation
MicroRNAs (miRNAs) were discovered in 1993 during a
developmental timing experiment in the nematode Cae-
norhabditis elegans. Currently, human miRNA family has
expanded to 2588 mature miRNAs (miRBase v21.0; http://
www.mirbase.org/) and in silico prediction estimates that
approximately 60% of human message RNA (mRNA) could be
targets of miRNA. These miRNAs account for only 1% of the
human genome. miRNAs are highly conserved in nearly all
organisms and constitute a class of non-coding RNAs, about
18e22 nucleotides long and play a crucial role in the
regulation of gene expression.18,19 Genes encoding miRNAsare transcribed by RNA polymerase II and form transcripts
as primary miRNAs (pri-miRNAs). pri-miRNAs are processed
by ribonuclease Drosha to produce precursor miRNAs (pre-
miRNAs) which is exported into the cytoplasm and cleaved
by the ribonuclease Dicer to produce mature, single
stranded miRNAs.19e21 Once synthesized, mature miRNA
binds to two proteins, GW182 and Argonaute/EIF2C (AGO)
family proteins and forms a complex called miRNA induced
silencing complex (miRISC) and mediate the target mRNA
recognition (Fig. 2). miRNA regulation takes place at mul-
tiple steps, including their transcription, their processing
by Drosha and Dicer, their loading onto AGO proteins and
miRNA turnover.20,21 miRNA transcription is controlled by
RNA Pol II-associated transcription factors and epigenetic
regulators. Transcription factors, such as p53, MYC, ZEB1
and ZEB2, and myoblast determination protein 1 (MYOD1)
positively or negatively regulate miRNA expression. Epige-
netic control, such as DNA methylation and histone modi-
fications also contribute to miRNA gene regulation. miRNA
identify target mRNA through specific base-pairing in-
teractions between the 50 end of miRNA and sites within
coding region and UTRs especially 30 UTR of mRNAs. The
domain at the 50 end of miRNAs that spans from nucleotide
position 2 to 7 is crucial for target recognition and has been
termed the ‘miRNA seed’. The downstream nucleotides of
miRNA (particularly nucleotide 8 and less importantly nu-
cleotides 13e16) also contribute to base pairing with the
targets. miRNAs with almost identical sequences at their 50
ends forms miRNA seed families and they share targets. For
example, miR-17, miR-20 and miR-106 belong to the same
family by sharing a common seed sequence and they target
a common gene, such as the cyclin-dependent kinase in-
hibitor 1A (CDKN1A; also known as p21). Moreover, 64% of
the human miRNAs are part of multimember seed families
and therefore, co-expression of seed-related miRNAs in-
duces a stronger downregulation of their common tar-
gets.22 miRNA inhibits the target gene expression either by
mRNA degradation or translational repression. The incom-
plete complementary binding leads to repression of trans-
lation or deadenylation of the target mRNA, whereas a
complete complementary binding leads to degradation of
the target mRNA. miRNA promotes mRNA cleavage by
inducing deadenylation or suppressing protein synthesis by
repressing the translation initiation at the cap recognition
or inducing ribosomes to drop off prematurely.19e21,23
Paradoxically, miRNA can also activate gene expression by
targeting gene regulatory sequences. miR-10a interacts
with the 50 UTR of mRNAs encoding ribosomal proteins to
enhance their translation.24 A putative target site for miR-
373 has been identified in the promoter of E-cadherin and
miR-373 overexpresssion has been shown to induce E-cad-
herin expression in prostate cancer cell line.25 In another
report, miR-369-3 is shown to be involved in the recruit-
ment of Ago and fragile X mental retardation related pro-
tein 1 (FXR1) genes and enhances the translation of tumor
necrosis factor (TNF) mRNA during cell cycle arrest.26 A
combinatorial nature of miRNA regulation i.e., each miRNA
regulates hundreds of different mRNAs allow miRNA to be a
part of complex regulatory networks in controlling gene
expression in almost every biological process including
development, immune response, aging, cell proliferation
and apoptosis.
Figure 2 miRNA biogenesis and regulation of gene expression. MicroRNAs (miRNAs) are small non-coding RNA synthesized from
protein coding genes or introns with the help of RNA polymerase II. (1) First, the miRNA gene transcribed to a primary long transcript
with stem loop structure as pri-miRNA. (2) This pri-miRNA is processed by RNase III family of enzymes, Drosha with the help of double
strandedRNAbinding protein, DGCR8 and produce smallw70-nucleotide precursor hairpin structure as precursormiRNA (pre-miRNA).
(3) Pre-miRNA then transported to the cytoplasm with the help of exportin5 protein. (4) Pre-miRNA was further cleaved by Dicer
together with transactivation-responsive (TAR) RNA-binding protein TRBP, in the cytoplasm and generate aw20-bp miRNA/miRNA*
duplex. Following processing, one strand of the miRNA/miRNA*duplex (the guide strand) is preferentially loaded into the miRNA-
induced silencing complex (miRISC) containing argonaute 2 (AGO2) and form mature miRNA. (5) Then, the mature miRNA targets
specific messenger RNA (mRNA) at the seed region that lead to either mRNA degradation or inhibition of protein synthesis.
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frequently involved in chromosomal alterations such as
deletion or amplification during tumor development.27
Therefore, it is not surprising that dysregulation of miRNA
networks have been associated with cancer progression.
Virus-host interactions also involve several regulatory steps
to control gene expression and one of them is changes in
cellular miRNA expression profiles. Cellular miRNAs control
protein expression that may influence cellular tropism of
viruses, modulate viral infectivity, and play a crucial role in
inducing appropriate antiviral immune responses.28 Several
RNA viruses have evolved mechanisms to degrade, boost, or
hijack cellular miRNAs to benefit the viral life cycle.29 HCV
infection exerts a profound effect on the expression of
cellular miRNAs.30 Some of the cellular miRNAs affect viral
replication directly by binding to the viral genome or indi-
rectly by targeting host factors.Direct interaction of cellular miRNAs to the
HCV genome
Recent studies have identified several miRNAs as key
players in virus-host interactions, regulating virusreplication and pathogenesis during HCV infection. The role
of miR-122 in HCV infection was first demonstrated by
sequestration of endogenous miR-122 that led to a sub-
stantial reduction in HCV RNA abundance.12 miR-122 binds
directly to 50 UTR of the virus genome at two adjacent sites
in association with Ago2. It forms an oligomeric complex in
which one miR-122 molecule binds to the 50 UTR of HCV RNA
with 30 overhanging nucleotides, masking the 50 terminal
sequences from nucleolytic degradation, thereby promot-
ing viral RNA stability and propagation of HCV genome.14,31
Furthermore, specific internal nucleotides as well as 30
terminal nucleotides in miR-122 were absolutely required
for maintaining HCV RNA.31 Recent study also demonstrated
that miR-122 protects HCV RNA from 50 decay by targeting
50 exonuclease Xrn1.32 HCV genome harbors two more
miR-122 target sites, one in the variable region of the 30UTR
and the other in the NS5B coding region. However, miR-122
binding to NS5B and 30UTR impairs HCV RNA replication and
translation.33 Exogenous expression of miR-122 allows effi-
cient HCV RNA replication and/or infectious virion pro-
duction in non-permissive cell line.34e36 Besides miR-122,
other miRNAs such as, miR-448, miR-196, miR-199a, let-7b
and miR-181c have been reported to interact directly with
HCV genome, however, upon binding to HCV RNA, they
miRNA in HCV infection 39inhibit HCV replication (Fig. 3). Overexpression of miR-448
and miR-196 were able to substantially attenuate viral
replication by directly targeting Core and NS5A coding re-
gion of the HCV genome, respectively.37 Overexpression of
miR-199a inhibited HCV replication in cells bearing HCV-1b
or -2a genome length replicon on binding to stem-loop II
region of 50UTR of HCV genome.38 Let-7b was also reported
to directly target HCV genome and elicits anti-HCV activ-
ity.39 Mutational analysis identified let-7b binding sites at
the coding sequences of NS5B and 50-UTR of HCV genome
that were conserved among various HCV genotypes. We
have recently showed that miR-181c is a novel miRNA that
binds to E1 and NS5A regions of HCV genome and over-
expression of miR-181c reduces the viral replication.40
However, miR-181c binding efficiency to genotype 1a and
genotype 2a specific HCV genome is different. Thus, further
work is needed to understand the association between
different genotypes of HCV genome and miRNAs.Cellular miRNAs that regulates HCV replication
by targeting interferon signaling pathway
HCV has developed several strategies to evade the IFN
signaling pathway to facilitate its own replication.41
HCV evades type I IFN pathway by inducing miRNAs that
regulate the expression of target genes involved in innate
immune response to viral infections. The direct correlation
of cellular miRNA in regulating type I IFN signaling pathway
to promote HCV replication was demonstrated by our
group. We established that HCV induces the expression of
miR-130a to evade IFN response by targeting IFITM1. Our
study demonstrated that miR-130a expression was upregu-
lated in liver biopsy from HCV infected patients as well as in
HCV infected hepatocytes in vitro.42 Knockdown of miR-
130a enhances IFITM1 expression that possesses anti-HCV
activity.43 During IFN treatment, IFITM1 accumulates at
hepatic tight junctions in the liver of HCV-infected patients
and then, interacts with HCV co-receptors, including CD81
and occludin, to disrupt the process of viral entry.44 Similar
observation of reduced HCV RNA copies was reported in
anti-miR-130a transfected virus infected cells.45 Subse-
quently, miR-130a expression was correlated with genes
involved in transforming growth factor beta (TGF-b)
signaling pathway and found to be reduced in HCV infectionFigure 3 Cellular miRNAs targeting HCV genome. The binding o
enhances viral replication and translation. The binding of miR-199
genome at two different locations, 50UTR and NS5B coding region
genome. miR-181c inhibits viral replication by targeting E1 and NSand upregulated on IFN treatment.45 However, another
study reported that overexpression of miR-130a inhibited
HCV replication by restoring the expression of endogenous
IFN-a and IFN-b and interferon stimulated genes, MxA,
ISG15 and USP18 respectively, in TLR3 and RIG-I deficient
hepatocytes.46 Upregulated miR-21 suppressed MyD88 and
IRAK1 expression in HCV infected hepatocytes, which sub-
sequently repressed type I IFN effector gene expression and
the type I IFN-mediated antiviral response, thereby pro-
moting viral replication.47 In a separate study, upregulation
of miR-758 expression was reported in HCV infected pa-
tients and shown to be negatively correlated with decrease
in TLR3 and TLR7 expression levels and thereby, reduced
IFN-a and IFN-b production to impair innate immune
response.48 Overexpression of miR-122 has also been asso-
ciated with inhibition of IFN signaling pathway. Silencing of
miR-122 enhances IFN-induced ISRE activity by decreasing
expression of SOCS3. This decrease in SOCS3 level was also
regulated by enhanced methylation at SOCS3 gene pro-
moter, implicating additional mechanism of inhibition of
HCV replication using antisense oligonucleotides of miR-
122.49 Recently, SOCS1 and SOCS3 were identified as the
targets of miR-221 and overexpression of miR-221 was
shown to accelerate anti-HCV effect of IFN-a in HCV
infected hepatocytes.50 IFN-a treatment also modulates
HCV-specific miRNAs expression in hepatocytes. miR-324-5p
and miR-489 were shown to be upregulated in the presence
of IFN-a while differential expression of miR-30c and miR-
130a were observed between HCV-infected Huh7.5 cells
treated with or without IFN-a.45 miR-30 cluster targets
SOCS1 and SOCS3 genes that act as negative regulators of
cytokine signaling. Specifically, SOCS1 and SOCS3 inhibit
JAK tyrosine kinase activity and STATs in the JAK-STAT
signaling pathway suggesting that IFN-a induced miRNAs
modulates gene expression in HCV infected hepatocytes.45
IFN-b treatment of Huh7 cells showed an upregulation of
miR-142-3p and miR-128a, and these miRNAs were down-
regulated in HCV replicon-expressing cells.51 IFN-b induced
miRNAs, in conjunction with downregulation of miR-122,
were also studied to prevent HCV replication. Introduc-
tion of anti-miRs against miR-196, miR-296, miR-351, miR-
431 and miR-448, with and without the inclusion of miR-122
mimic, attenuated the IFN-b mediated reduction of viral
RNA by w75%.37 In a recent study, a set of 750 miRNAs
expression profiles was generated in response to IFN-a andf two copies of miR-122 within the 50 UTR of the HCV genome
a at 50UTR inhibits viral replication. Let-7b interacts with viral
. miR-448 targets Core and miR-196 targets NS5A of the HCV
5A regions of viral genome.
40 S. Shrivastava et al.interleukin (IL)-28B treatment to hepatocytes. Let-7b was
shown to inhibit HCV replication and viral protein trans-
lation by targeting host factor insulin-like growth factor 2
mRNA-binding protein 1 (IGF2BP1). Furthermore, inhibition
of let-7b attenuated the anti-HCV effects of IFN-a and IL-
28B.52 We recently observed that miR-373 was upregulated
during HCV infection and negatively regulated type I IFN
signaling pathway by suppressing JAK1 and IRF9 (unpub-
lished observation). Together, these observations suggest
that type I and type III IFNs induced host miRNAs directly
involved in regulation of HCV replication and infectivity
along with targeting host factors resulting in additional
mode of virus restriction.Cellular miRNAs in response to IFN therapy and
HCV infection
Increasing evidence suggests that miRNAs have a profound
impact on host defense to HCV infection and clinical
outcome of standard HCV therapy. miRNA expression pro-
files were examined to identify the miRNAs associated with
the standard treatment (IFN-a with RBV) to chronic hepa-
titis C (CHC) patients. Expression levels of 9 miRNAs
(upregulated: miR-27b, miR-122, miR-378 and miR-422b;
downregulated: miR-18a, miR-34b, miR-143, miR-145 and
miR-652) were significantly different in the SVR and non-
responder (NR) groups, suggesting that expression pattern
of these hepatic miRNA are associated with the therapeutic
outcome in CHC patients.53 The expression level of hepatic
miR-122 was reportedly associated with early response to
IFN treatment. HCV infected patients who did not respond
to therapy had significantly lower miR-122 levels as
compared to responder.54 In addition, an association be-
tween miR-122, IFN-l3 polymorphism and outcome to IFN
therapy was examined in chronic HCV patients. HCV
infected patients with IFN-l3 CC genotype, favorable
outcome to therapy, were associated with increased he-
patic expression of miR-122. Interestingly, during PEG-IFN/
RBV therapy, patients with the IFN-l3 CC genotype had a
more rapid early HCV viral decline than patients with CT/
TT genotype and a stronger association of miR-122 was
observed with complete early virologic response (cEVR)
than with SVR. This implies that miR-122 expression may
play an important role during early viral decline induced by
the innate immune response.55 In a recent study, the ki-
netics of serum levels of miR-122 was determined during
IFN therapy. miR-122 expression in sera remained low in
SVR, but increased to baseline levels in patients not
responding or showing relapse to therapy, suggesting that
serum miR-122 levels reflect the response rate to IFN/RBV
therapy in chronic HCV patients.56 Higher levels of miR-27a
displayed favorable response to IFN-a and RBV combination
therapy.57 Serum levels of miR-181a were significantly
elevated in SVR patients following treatment compared to
NR patients and treatment-naı¨ve SVRs.58 IFN-l3 expression
is strongly associated with favorable response to IFN-a and
RBV in HCV infected patients. However, HCV infection in-
duces the expression of miR-208b and miR-499a-5p, which
in turn downregulates IFN-l3 expression. The unfavorable
IFN-l3 polymorphism at rs4803217 SNP: T genotype was
targeted by miR-208b and miR-499a-5p and decreases IFN-l3 mediated antiviral response. Inhibition of miR-208b and
miR-499a-5p represents a therapeutic option to improved
response rate to IFN-a and RBV with unfavorable IFN-l3
genotype.59 Hepatic miR-155 expression was significantly
elevated in HCV-infected patients. Lower viral load in sera
and SVR to standard treatment was found to be associated
with elevated levels of miR-155 in HCV infected patients. In
addition, miR-155 was significantly elevated in HCV infec-
ted patients harboring the favorable IL-28B CC allele
(rs1279860).60 Treatment-naı¨ve patients with chronic HCV
infection were shown to have higher expression of miR-155
in their circulating monocytes as compared to individuals
who cleared HCV infection after therapy, suggesting a
possible correlation between increased miR-155 in mono-
cytes and HCV viral presence and/or replication.61 Expres-
sion profiling of peripheral blood mononuclear cells (PBMC)
associated miRNAs was also compared between responder
and non-responders to PEG-IFN/RBV antiviral therapy for
chronic HCV patients. Circulating PBMC associated miR-
125b was a predictive marker for SVR with significantly
reduced levels of miR-125b in responders versus non-
responders.62Cellular miRNAs in HCV mediated liver disease
progression
HCV modulates the expression of miRNAs to regulate crit-
ical gene networks that help in determining viral load,
clearance and HCV related disease progression. Recently,
in vivo kinetics of hepatic and serum miR-122 and viral
replication was studied in HCV infected chimpanzees to
understand the complexities of the virus-host interaction
during the acute phase of HCV infection. It was observed
that during acute infection (first 4 weeks) there was rise in
hepatic miR-122 levels indicating the significance of miR-
122 in viral replication. However, in later time points
(10e14 weeks), an inverse correlation between hepatic
miR-122 and HCV RNA in the liver and serum was noted.
Subsequently, there is rise of hepatic miR-122 level during
HCV clearance and alanine leucine transaminase (ALT)
normalization suggesting a tri-phasic relationship among
hepatic miR-122 expression and viral RNA levels during HCV
infection.63 Apart from regulating viral replication, miR-122
is also involved in cell cycle progression in hepatoma cell
line by regulating viral translation.64 Ectopic expression of
miR-122 promotes HCV IRES dependent translation during
the G₀ and G₁ phase of cell cycle.64 Alcohol consumption
increases viral replication by regulating miR-122 and cyclin
G1 expression and use of miR-122 inhibitor has been re-
ported to prevent alcohol-induced increase in HCV RNA and
protein levels.65 In addition, alcohol consumption enhances
miR-122 expression by increasing the expression levels of
GW182 and heat shock protein 90 further promoting HCV
replication.66 Overexpression of miR-122 also decreases
HCV entry into hepatocytes through down-regulation of
occludin.67 Apart from directly targeting the viral genome,
miR-196a targets Bach1, a repressor of anti-oxidative and
anti-inflammatory heme oxygenase1 (HMOX1) and inhibits
HCV RNA and NS5A protein expression in subgenomic
replicon.68 In addition, higher HMOX1 expression was
correlated with higher expression of Bach1 and miR-122 in
miRNA in HCV infection 41chronic HCV patients.69 Several miRNA profiling studies
have demonstrated alterations in miRNAs expression and
identified miRNA-mRNA regulatory networks during HCV
infection.51,70e72 Differential upregulation of hsa-miR-
130a, hsa-miR-130b, hsa-miR-298, hsa-miR-193a-5p and
hsa-miR-371-5p were observed in HCV Con1 replicon in
comparison to control cells. These miRNAs have been
associated with cell growth by targeting genes PPARG, IRF1
and STAT3 in HCV infected cells.71 Differential expression
of miRNAs such as, miR-24, miR-149, miR-638 and miR-1181
were also identified following HCV infection and are
involved in HCV entry, replication and propagation.72
Chronic HCV infection is closely associated with hepatic
inflammation, fibrosis, steatosis, liver cirrhosis and HCC.
Chronic HCV infection induced liver fibrosis is mediated by
upregulation of TGF-b.73 TGF-b signaling activates hepatic
stellate cells (HSCs) to induce extracellular matrix pro-
duction. In HCV-infected patients and in a mouse carbon
tetrachloride fibrosis model, expression levels of miR-21
were higher and found to be positively correlated with
fibrotic stage.74 miR-21 was shown to target SMAD7, a
negative regulator of TGF-b signaling, leading to increased
fibrogenesis.74 In HCV infected patients, lower expression
levels of miR-29 was observed in liver and overexpression
of miR-29 inhibits viral RNA in HCV infected hepatocytes.75
Inhibition of miR-29 was also linked with activation of
HSCs and collagen synthesis.75 Recently, upregulation of
miR-200c was linked with hepatic fibrosis in HCV patients.
miR-200c reduces the expression of Fas associated phos-
phatase 1 (FAP1) and subsequent activation of Src kinase
signaling increases the expression of collagen and fibro-
blast growth factor involved in fibrosis.76 Reduced
expression of miR-449a and miR-107 was observed in
chronic HCV patients but not in alcoholic and non-
alcoholic liver diseases by genome wide miRNA ana-
lyses.77,78 miR-449a regulates the expression of YKL40 by
targeting NOTCH signaling pathway following HCV infec-
tion.77 Elevated levels of YKL40 were observed in chronic
HCV patients and YKL40 is known to promote the synthesis
of extracellular matrix and fibrosis. Downregulation of
miR-107 and miR-449a modulates the expression of CCL2
chemokine by targeting components of the interleukin-6
receptor (IL-6R) complex in patients with HCV related
liver disease. miR-449a and miR-107 target IL-6R and JAK1
respectively and inhibit IL-6 signaling and impair STAT3
activation in human hepatocytes.78 Collectively, these
reports suggest the role of miRNAs in targeting genes
involved in linking inflammation and fibrosis in chronic
HCV infection. The incidence of hepatic steatosis is higher
in patients infected with genotype 3a of HCV.79 The role of
miR-27 was implicated in HCV associated steatosis by two
separate groups. In the first study, miR-27a was reported
to targets lipid metabolism related transcription factor,
RXRa and lipid transporter, ABCA1 resulting in lipid accu-
mulation and HDL synthesis in virus infected hepato-
cytes.57 In a second study, miR-27b also induced lipid
droplet accumulation in HCV infected hepatocytes by
targeting peroxisome proliferator-activated receptor
(PPAR-a) and angiopoietin-like protein 3 (ANGPTL3).80
miR-27a repression increased the cellular lipid content,
decreased the buoyant density of HCV particles and
increased viral replication and infectivity.57 However,miR-27a expression was induced by HCV infection and HCV
replication was hampered by miR-27a reflecting a nega-
tive feedback role in HCV infection. In a separate study,
upregulation of miR-136 and downregulation of miR-126
and miR-181a was observed in liver biopsies of HCV
infected patients with different genotypes compared with
noninfected individuals. Interestingly, miR-122 and miR-
126 expression levels were correlated with viral load in
sera and miR-136 and miR-122 correlated with the pres-
ence of steatosis.81
CHC is a major risk factor associated with HCC.82 miRNA
dysregulation has been linked with initiation and progres-
sion of HCC,83e85 however, the role of miRNAs in HCV-
related HCC is poorly understood. The identification of
HCC related miRNA signatures is of great value for the
early diagnosis of HCC, prior to the onset of disease in HCV-
positive patients. HCV modulates miRNA expression to
facilitate hepatocyte growth towards tumorigenesis by
regulating various signaling pathways. We have observed
reduced expression of miR-181c at the transcriptional level
in HCV infected hepatocytes. miR-181c targets HOXA1 to
promote hepatocyte growth by modulating Stat3 and Stat5
expression during HCV infection.40 miR-155 expression
levels were markedly increased in patients infected with
HCV. Overexpression of miR-155 promoted the cell prolif-
eration through activation of b-catenin and a concomitant
increase in cyclin D1, c-myc, and survivin. miR-155 also
reduces the expression of adenomatous polyposis coli
(APC), a negative regulator of Wnt signaling, to promote
hepatocyte proliferation and tumorigenesis.86 In contrast,
miR-141 inhibits the expression of tumor suppressor gene,
DLC-1 (a Rho GTPase-activating protein) to enhance viral
replication and tumorigenesis in HCV-infected primary
human hepatocytes.87 HCV core protein is a known onco-
gene involved in HCV mediated tumorigenesis. In a recent
study, core overexpression significantly reduces miR-152
expression in HepG2 cells. miR-152 directly target Wnt1,
a activating ligand for b-catenin pathway therefore,
inhibiting Wnt signaling.88 Reduced expression of miR-491
promotes tumorigenesis by inhibiting phosphoinositol-3 ki-
nase (PI3K)-Akt prosurvival pathway in chronic HCV infec-
tion. miR-192/miR-215 and miR-491 are capable of
enhancing HCV replication in replicon cells.89 Limited
studies are available addressing the role of miRNA
expression in HCV associated HCC. Differential miRNA
expression from formalin fixed paraffin embedded HCV
infected HCC specimens indicated 10 upregulated and 19
downregulated miRNAs.90 Another study in HCV infected
patients, 13 miRNAs were shown to be downregulated and
were predicted to target genes related to immune
response, antigen presentation, cell cycle, proteasome,
and lipid metabolism signaling pathways.91 However, vali-
dation of these miRNAs and their predicted targets are
needed to elucidate the conclusive role of particular
miRNA in HCV related HCC.Circulatory miRNAs as biomarkers in HCV
infection
One of the major challenges in HCV research is the detec-
tion of early stage liver disease which will allow for rapid
42 S. Shrivastava et al.intervention and improved outcome of antiviral treatment.
Non-invasive or minimally invasive methods need to be
developed to evaluate disease severity and the likelihood
of disease progression. Circulating miRNAs might have po-
tential value as biomarkers for detection and as predictive
marker for liver disease progression in HCV infection.
Circulating miRNAs are released in extracellular space and
carried in various forms, including in association with Ago2,
exosomes or HDL in circulation.92,93 The biological function
of these circulating miRNA is still unknown in HCV infection.
However, circulating miRNA might provide a means of
communication to neighboring recipient cells and influence
gene expression on target cells. To determine the potential
of developing circulating miRNA as predictive biomarker in
HCV related liver disease, we performed serum/plasma
specific miRNA array and observed that several circulating
miRNAs were significantly upregulated in sera of HCV
infected patients as compared to healthy controls.94 We
observed increased expression of miR-20a and miR-92a in
sera specific to HCV associated liver disease but not in sera
of patients with non-HCV related liver disease. Subse-
quently, we observed that elevated levels of miR-20a were
positively correlated with disease severity in HCV infected
patients, however, miR-92a expression was reduced with
higher grade of fibrosis in HCV infected patients.94 Longi-
tudinal sample analyses suggested that miR-20a expression
remained higher when disease progresses from acute to
chronic infection whereas, miR-92a expression declines in
response to spontaneously resolved infection. miRNA
profiling was also performed to identify the expression of
940 human miRNAs in the serum of HCV infected in-
dividuals. Serum levels of miR-134, miR-320c and miR-483-
5p were significantly upregulated in HCV infected pa-
tients.95 Serum levels of miR-122 were correlated with
disease parameters in patients with CHC by several groups.
The higher levels of miR-122 and miR-192 were observed in
sera from patients with CHC and in other etiologiesFigure 4 Schematic representation of HCV infection associated
miRNAs regulates the expression of genes involved in several signa
metabolism, inflammation and fibrosis linked with HCV induced livassociated with liver injury as compared to sera from
healthy controls.96e100 The serum level of miR-122 and miR-
21 strongly correlates with serum ALT levels and higher
necroinflammatory activity in the liver of CHC patients
suggesting their potential as better serum biomarker over
ALT in predicting the presence of chronic HCV infec-
tion,56,96,97,100,101 although the specificity of miR-122 for
HCV mediated liver disease is controversial. Reduced levels
of miR-122 were observed in both serum and liver samples
from patients with CHC with advanced fibrosis. During
fibrosis progression, the number of hepatocytes decreases
and numbers of lymphocytes, Kupffer cells, and HSCs in-
creases. This may explain the reduced amount of miR-122
with hepatocyte loss at advanced stage of fibrosis.55,102
miR-221 was found to be upregulated in the serum of CHC
patients.50 miR-181a expression was significantly upregu-
lated in the serum of HCV patients compared to the healthy
controls.58 The serum miR-181a expression level in HCV
patients is inversely correlated with the level of viremia, as
well as liver enzymes (ALT, AST). Levels of miR-125b and
miR-146a were also increased in the serum of CHC patients
compared to healthy controls.61
Circulating miRNAs in urine were also examined for
developing screening methods. Expression of three upre-
gulated miRNAs, miR-625, miR-532 and miR-618, were
evaluated as non-invasive biomarkers for early diagnosis of
HCC among high-risk HCV positive patients. Elevated
expression of miR-625, miR-532 and miR-618 were observed
in 56%, 62.5% and 72% of HCC-post HCV positive patients,
respectively. In addition, miR-516-5p and miR-650 were
found to be down-regulated in 50% and 72% of HCC-post
HCV positive patients, respectively. Differential expres-
sions of these miRNAs were predicted to possibly target
genes related to HCC development and progression in high
risk HCV patients.103 Further studies are warranted to un-
derstand the function of these extracellular circulating
miRNAs during HCV infection.miRNAs in liver disease progression. Modulated expression of
ling pathways such as, IFN signaling, hepatocyte growth, lipid
er disease.
miRNA in HCV infection 43Conclusion
Cross-talk between miRNA and HCV is an emerging area of
research. Understanding the potential of manipulating
miRNAs as a therapeutic option either alone or in combi-
nation with currently available drugs to treat HCV infected
patients is still in preliminary stage. Direct involvement of
miR-122 in regulating viral replication and pathogenesis has
led to the development of the very first miRNA based
antiviral therapy. Therapeutic silencing of miR-122 showed
long lasting antiviral activity in treatment of naı¨ve HCV
patients and no off-target effects in clinical trials. HCV
infection modulates several miRNAs that regulate host im-
mune response and cell growth interconnected with mul-
tiple signaling pathways (Fig. 4). miRNA mediated
regulation of gene expression will help in identifying
important signaling networks required towards HCV asso-
ciated liver disease progression. Indeed, further in-depth
studies are needed to identify the mechanistic insights
behind modulated miRNAs by HCV infection. Therefore, the
identification of miRNAs with a prominent role in HCV viral
life cycle and its implication in liver disease progression is
exploring a new frontier in the discovery of novel drugs
against chronic HCV infections. MicroRNA in circulation is a
growing area of research and there are challenges ahead in
understanding the cellular origin and functional role of
circulatory miRNAs in liver disease progression. Recent
studies on circulating miRNAs generate a potential for
development of predictive or diagnostic biomarkers to
categorize patients with high risk groups for developing end
stage liver disease during HCV infection. In addition, cir-
culatory miRNAs is emerging as a tool to assess therapeutic
outcome in response to therapy in HCV infected patients.
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